Day: April 27, 2020

Ongoing Impacts of COVID-19 Pandemic Constitute “Material Adverse Effect”Company Intends to Explore Other Strategic Collaborations with EOSTerminates Debt Commitment of up to $160 Million to Finance Acquisition and Retire Existing DebtCARLSBAD, Calif., April 27, 2020 (GLOBE NEWSWIRE) —  Alphatec Holdings, Inc. (“ATEC” or the “Company”) (Nasdaq: ATEC), a medical device company dedicated to revolutionizing the approach to spine surgery, announced today that it has terminated the Tender Offer Agreement (“TOA”), dated February 26, 2020, under which it was to acquire EOS imaging, SA (“EOS”), for up to $88 million, plus debt retirement of $33.9 million, in a combination of cash and equity.This decision follows ATEC’s consideration and analysis of the expected ongoing market effects of the COVID-19 pandemic. Based upon its assessment,...

WISeKey’s WIShelter App now includes a health digital certificate allowing users to share their medical status via a secure QRCODEThe app can be downloaded from www.wishelter.comWISeKey is currently working with several governments and health organizations to add functionalities to the WIShelter app such as the ability to update the user status with the results of their COVID-19 testGeneva, Switzerland – April 27, 2020: WISeKey International Holding Ltd. (“WISeKey”) (SIX: WIHN, NASDAQ: WKEY), a leading global cybersecurity and IoT company, today announced the launch of WIShelter Version 2, its new application in the WISeID App ecosystem, designed to remediate risks during the global COVID-19 lockdown period. Using their digital identity secured by WISeKey, users will be able to geo-localize other certified users and stablish secure communications....

Pratteln, Switzerland, April 27, 2020 – Santhera Pharmaceuticals (SIX: SANN) has entered into a collaboration agreement with Cold Spring Harbor Laboratory (CSHL) to investigate the potential of lonodelestat (POL6014), a potent inhibitor of human neutrophil elastase (hNE), as a therapeutic intervention for COVID-19-related acute respiratory distress syndrome (ARDS).Researchers at CSHL are part of a recently formed consortium of international non-clinical and clinical experts called the ‘NETwork to target neutrophils in COVID-19’. This NETwork will study the role of neutrophils and neutrophil extracellular traps (NETs) in the pathology of COVID-19 as well as hNE and other targets for intervention for the purpose of treating COVID-19 [1, 2].NETs are macromolecular structures of DNA and proteins that neutrophils can expel, for example during...

Pratteln, Schweiz, 27. April 2020 – Santhera Pharmaceuticals (SIX: SANN) hat eine Vereinbarung zur Zusammenarbeit mit dem Cold Spring Harbor Laboratory (CSHL) abgeschlossen, um das Potenzial von Lonodelestat (POL6014), einem potenten Inhibitor der humanen neutrophilen Elastase (hNE), als therapeutische Intervention bei COVID-19-bedingtem akutem Atemnotsyndrom (ARDS) zu untersuchen.

27 April 2020 – Kvaerner has in the first quarter taken several precautionary steps to safeguard employees, suppliers and local societies against the risks of the corona virus development. The financial results are negatively impacted by provisions related to covid-19. For the results in 2020 as a whole, it is too early to estimate the total effects. Kvaerner has demobilised the majority of hired-in personnel working on ongoing projects, office staff is working from home offices and several virus precautions influence daily work at the yards. Still, operations are continuing, and ongoing projects are moving forward with reduced capacity.For the first quarter this year, revenues were NOK 2 192 million for the Field Development segment, compared to NOK 2 158 million one year ago. The corresponding EBITDA results were negative NOK 132 million...

27. april 2020 – Kværner har i første kvartal tatt flere forholdsregler for å beskytte ansatte, leverandører og lokalsamfunn mot risikoen for smittespredning av korona. De finansielle resultatene påvirkes negativt av kostnadsavsetninger knyttet til covid-19. For resultatene i 2020 som helhet, er det for tidlig å estimere de totale effektene. Kværner har demobilisert flertallet av innleid personell som jobbet med pågående prosjekter, kontoransatte jobber på hjemmekontor og andre smittevernstiltak påvirker det daglige arbeidet på verftene. Til tross for dette så forsetter driften, og pågående prosjekter går videre med redusert kapasitet.For første kvartal i år var inntektene 2 192 millioner kroner for Field Development-segmentet, mot 2 158 millioner kroner for et år siden. Tilsvarende EBITDA-resultater var minus 132 millioner kroner...

ID-Sparinvest, Filial af Sparinvest S.A., Luxembourg har tidligere observeret usædvanlige markedsforhold på grund af udviklingen i situationen med Covid–19 virussen. Der blev derfor indført midlertidigt forhøjet emissionstillæg og indløsningsfradrag for foreningens afdelinger/andelsklasser. Markedsforholdene for obligationer er siden forhøjelsen vendt tilbage til mere normale tilstande, og derfor er der gennemført en yderligere delvis nedsættelse af de forhøjede emissionstillæg og indløsningsfradrag i udvalgte afdelinger/andelsklasser.Vedhæftet denne fondsbørsmeddelelse er en oversigt over ændringerne i emissionstillæg og indløsningsfradrag i de pågældende afdelinger/andelsklasser. De nye emissionstillæg og indløsningsfradrag er gældende på andelsklasseniveau i afdelinger med andelsklasser.Henvendelser vedrørende nærværende fondsbørsmeddelelse...

VANCOUVER, British Columbia, April 27, 2020 (GLOBE NEWSWIRE) — ValOre Metals Corp. (“ValOre” or the “Company”; TSX‐V: VO) today announced board approval for the proposed 2020 core drilling exploration program at ValOre’s 100%-owned Pedra Branca Platinum Group Element Project (“PGE”, “2PGE+Au”) in northeastern Brazil. ValOre also announced that it has entered into a C$1.2 million unsecured revolving credit facility to fully fund the first phase of the proposed drill program at Pedra Branca.“We are excited to begin drilling Pedra Branca and to really showcase the compelling potential of our PGE project,” stated Jim Paterson, Chairman & CEO. “We have identified many new high-priority targets in our two-phase program, which is designed to expand the current resource, advance existing targets and test undrilled areas....

Rockville, MD, April 27, 2020 (GLOBE NEWSWIRE) —MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced data related to flotetuzumab, an investigational, bispecific CD123 x CD3 DART® molecule being evaluated in patients with refractory acute myeloid leukemia (AML). The data will be presented during a plenary session at the American Association for Cancer Research (AACR) Virtual Annual Meeting I, taking place April 27-28, 2020.“Patients with TP53 mutated AML respond poorly to induction therapy and have a dismal prognosis. The current study suggests that TP53 mutational status correlated with an immune-infiltrated tumor microenvironment that was associated with response to flotetuzumab...

SHANGHAI, China, April 26, 2020 (GLOBE NEWSWIRE) — Hua Medicine (the “Company”, Stock Code: 2552. HK) today announces the positive results of the clinical study HMM0112.HMM0112 is a Phase I trial conducted in the United States in Type 2 Diabetes (T2D) patients with insufficiently controlled blood glucose levels while on metformin, DPP-4 inhibitors or SGLT-2 inhibitors, alone or in combination treatment. The principal purpose of HMM0112 is to investigate the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of dorzagliatin and empagliflozin (a SGLT-2 inhibitor) as either monotherapy or combination therapy. The PK results demonstrated no impact of dorzagliatin (75 mg BID) and empagliflozin (25 mg QD) on their respective PK properties under co-administration, supporting their combination use in the clinical setting, while...